Who Supplies Azithromycin to India from URUGUAY

To import finished pharmaceutical formulations containing Azithromycin (HS Code 30042064) into India, the following regulatory requirements must be met:

1. 1Import License: Importers must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Drug Registration: The Central Drugs Standard Control Organisation (CDSCO) requires registration of the drug. This involves submitting Form 40/41, along with a No Objection Certificate (NOC) from the manufacturer.
3. 3Approval Process: The Drug Controller General of India (DCGI) evaluates the application, which may take several months.
4. 4Compliance: The product must comply with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

The registration process can take several months, depending on the completeness of the application and the workload of the regulatory authorities.

Imported finished pharmaceutical formulations containing Azithromycin must undergo quality testing to ensure compliance with Indian standards:

1. 1Testing Requirements: Samples are tested in CDSCO-approved laboratories for identity, purity, strength, and quality.
2. 2Batch Certification: Each batch requires a Certificate of Analysis (CoA) from the manufacturer, detailing the product's specifications and testing results.
3. 3Stability Data: Stability studies must be conducted under ICH Zone IV conditions to demonstrate the product's shelf-life in India's climate.
4. 4Pharmacopoeia Standards: The product must meet the standards set by the Indian Pharmacopoeia.
5. 5Port Inspection: Customs drug inspectors may conduct inspections at ports to verify compliance with regulatory requirements.

Failure to meet these requirements can result in delays or rejection of the import consignment.

Recent developments affecting the import of finished pharmaceutical formulations containing Azithromycin into India include:

1. 1Regulatory Updates: The CDSCO has streamlined the registration process for certain pharmaceutical products to expedite market entry.
2. 2PLI Scheme Impact: The Production Linked Incentive (PLI) scheme has been extended to encourage domestic manufacturing, potentially affecting the volume of imports.
3. 3Bilateral Agreements: India has engaged in discussions with Uruguay to facilitate pharmaceutical trade, including mutual recognition of Good Manufacturing Practices (GMP).

These changes aim to balance the promotion of domestic manufacturing with the need for imported pharmaceutical products.

India imports finished Azithromycin formulations to meet domestic demand for this antibiotic, which is used to treat various infections. The demand is driven by:

1. 1Patented Formulations: Innovative formulations not yet available domestically.
2. 2Specific Dosage Forms: Unique forms such as extended-release tablets or pediatric suspensions.
3. 3Domestic Capacity: Limited domestic production capacity for certain formulations.

The market size for Azithromycin in India is substantial, with imports supplementing domestic production to meet healthcare needs.

The import duty structure for finished pharmaceutical formulations containing Azithromycin (HS Code 30042064) into India is as follows:

1. 1Basic Customs Duty (BCD): 10% of the Cost, Insurance, and Freight (CIF) value.
2. 2Social Welfare Surcharge (SWS): 10% of the BCD, totaling 1% of the CIF value.
3. 3Integrated Goods and Services Tax (IGST): 12% of the CIF value.

The total landed duty is approximately 32.36% of the CIF value. Importers should account for these duties when calculating the total cost of imported goods.

Uruguay's pharmaceutical industry offers several advantages for exporting finished Azithromycin formulations to India:

1. 1Regulatory Compliance: Uruguayan manufacturers adhere to international standards, ensuring product quality.
2. 2Unique Formulations: Specialized dosage forms or patented formulations not available from other suppliers.
3. 3Competitive Pricing: Potential for cost-effective pricing due to favorable exchange rates and efficient manufacturing processes.

While other countries like China, Germany, and the United States also supply Azithromycin formulations to India, Uruguay's unique offerings and compliance with international standards position it as a competitive source.

India imports finished Azithromycin formulations from Uruguay due to:

1. 1Regulatory Compliance: Uruguayan manufacturers adhere to international standards, ensuring product quality.
2. 2Unique Formulations: Availability of specialized dosage forms or patented formulations not produced domestically.
3. 3Competitive Pricing: Favorable exchange rates and efficient manufacturing processes offer cost advantages.

These factors make Uruguay a strategic source for Azithromycin formulations.

When compared to other sources like China, the European Union, and the United States, Uruguay offers: